地西他滨治疗骨髓增生异常综合征研究进展
|
摘要
目前去甲基化药物地西他滨(DAC)治疗骨髓增生异常综合征(MDS)的疗效已得到普遍认可且已广泛应用于临床。本文简述其治疗作用机制及近年DAC对不同分型MDS治疗及其剂量、联合用药、分子学标志物预测、不良反应,总结现有临床及实验研究资料,为今后的精准用药治疗提供经验及参考。
The efficacy of the demethylating drug decitabine(DAC) in the treatment of myelodysplastic syndrome(MDS) has been widely recognized and widely used in clinical practice. This article briefly describes its therapeutic mechanism and recent DAC treatment of different types of MDS and its dose, combination, molecular marker prediction, adverse reactions, summarizing existing clinical and experimental research data, providing experience for future accurate drug treatment and reference.
The efficacy of the demethylating drug decitabine(DAC) in the treatment of myelodysplastic syndrome(MDS) has been widely recognized and widely used in clinical practice. This article briefly describes its therapeutic mechanism and recent DAC treatment of different types of MDS and its dose, combination, molecular marker prediction, adverse reactions, summarizing existing clinical and experimental research data, providing experience for future accurate drug treatment and reference.
引文
[1]薄利魁.地西他滨单药五天方案治疗复杂核型骨髓增生异常综合征和急性髓系白血病临床分析[J].健康前沿,2016,23(1):67-68.
[2]Wu L,Li X,Chang C,et al.Efficacy and Toxicity of Decitabine versus CHG Regimen(Low-dose Cytarabine, Homoharringtonine and Granulocyte Colony-stimulating Factor)in Patients with Higher Risk Myelodysplastic Syndrome:a Retrospective Study[J].Leukemia&Lymphoma,2016,57(6):1367-1374.
[3]Gao S,Li Z,Fu JH,et al.Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively[J].Asian Pacific Journal of Cancer Prevention Apjcp,2015,16(15):6627-6632.
[4]Garcia-Manero G,Couriel DR,Tambaro FP,et al.A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome(MDS)[J].Blood,2009,114(22):119.
[5]Jabbour EJ,Garciamanero G,Strati P,et al.Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium[J].Cancer,2015,121(6):876-882.
[6]叶丽,任艳玲,谢丽丽,等.小剂量地西他滨治疗较低危骨髓增生异常综合征患者疗效初步观察[J].中华血液学杂志,2017,38(4):307.
[7]Steensma DP,Baer MR,Slack JL,et al.Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes:The Alternative Dosing for Outpatient Treatment(ADOPT)Trial[J].Journal of Clinical Oncology,2009,27(23):3842-3848.
[8]赵龙,席亚明,郭敏,等.小剂量地西他滨治疗中高危骨髓增生异常综合征的Meta分析[J].肿瘤防治研究, 2013,40(5):473-477.
[9]Li X,Song Q,Chen Y,et al.Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome:A Retrospective Analysis[J].PLoS One,2014,9(4):e95473.
[10]李萨萨,陶千山,蒲莲芳,等.超小剂量地西他滨治疗骨髓增生异常综合征的近期疗效和不良反应观察[J].安徽医药,2016,20(6):1174-1178.
[11]陈亚丽,郭荣,李英梅,等.低剂量地西他滨治疗中高危骨髓增生异常综合征患者38例疗效观察[J].中华实用诊断与治疗杂志,2016,30(6):620-622.
[12]Wei G,Ni W,Chiao J,et al.A meta-analysis of CAG(cytarabine, aclarubicin, G-CSF)regimen for the treatment of 1029patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Journal of Hematology&Oncology,2011,4(1):46.
[13]黄达永,付丽,魏娜,等.小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察[J].白血病·淋巴瘤,2016,25(7):406-408.
[14]高苏,仇惠英,金正明,等.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965.
[15]Chen W,Zhao W,Yang H,et al.Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome[J].Leukemia Research,2015,39(4):424.
[16]Wu P,Liu L,Weng J,et al.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide(ATO)in the Human Myelodysplastic Syndrome Cell Line SKM-1[J].Indian Journal of Hematology&Blood Transfusion,2016,32(4):412-417.
[17]Adès L,Itzykson R,Fenaux P.Myelodysplastic syndromes[J].Lancet,2014,383(9936):2239-2252.
[18]Traina F,Visconte V,Elson P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia,2014,28(1):78-87.
[19]Wu L,Shi W,Xiao L,et al.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome[J]. Journal of Translational Medicine,2016,14(1):66.
[20]Wang J,Yi Z,Wang S,et al.The effect of decitabine on megakaryocyte maturation and platelet release[J].Thrombosis&Haemostasis,2011,106(2):337-343.
[2]Wu L,Li X,Chang C,et al.Efficacy and Toxicity of Decitabine versus CHG Regimen(Low-dose Cytarabine, Homoharringtonine and Granulocyte Colony-stimulating Factor)in Patients with Higher Risk Myelodysplastic Syndrome:a Retrospective Study[J].Leukemia&Lymphoma,2016,57(6):1367-1374.
[3]Gao S,Li Z,Fu JH,et al.Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively[J].Asian Pacific Journal of Cancer Prevention Apjcp,2015,16(15):6627-6632.
[4]Garcia-Manero G,Couriel DR,Tambaro FP,et al.A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome(MDS)[J].Blood,2009,114(22):119.
[5]Jabbour EJ,Garciamanero G,Strati P,et al.Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium[J].Cancer,2015,121(6):876-882.
[6]叶丽,任艳玲,谢丽丽,等.小剂量地西他滨治疗较低危骨髓增生异常综合征患者疗效初步观察[J].中华血液学杂志,2017,38(4):307.
[7]Steensma DP,Baer MR,Slack JL,et al.Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes:The Alternative Dosing for Outpatient Treatment(ADOPT)Trial[J].Journal of Clinical Oncology,2009,27(23):3842-3848.
[8]赵龙,席亚明,郭敏,等.小剂量地西他滨治疗中高危骨髓增生异常综合征的Meta分析[J].肿瘤防治研究, 2013,40(5):473-477.
[9]Li X,Song Q,Chen Y,et al.Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome:A Retrospective Analysis[J].PLoS One,2014,9(4):e95473.
[10]李萨萨,陶千山,蒲莲芳,等.超小剂量地西他滨治疗骨髓增生异常综合征的近期疗效和不良反应观察[J].安徽医药,2016,20(6):1174-1178.
[11]陈亚丽,郭荣,李英梅,等.低剂量地西他滨治疗中高危骨髓增生异常综合征患者38例疗效观察[J].中华实用诊断与治疗杂志,2016,30(6):620-622.
[12]Wei G,Ni W,Chiao J,et al.A meta-analysis of CAG(cytarabine, aclarubicin, G-CSF)regimen for the treatment of 1029patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Journal of Hematology&Oncology,2011,4(1):46.
[13]黄达永,付丽,魏娜,等.小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察[J].白血病·淋巴瘤,2016,25(7):406-408.
[14]高苏,仇惠英,金正明,等.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965.
[15]Chen W,Zhao W,Yang H,et al.Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome[J].Leukemia Research,2015,39(4):424.
[16]Wu P,Liu L,Weng J,et al.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide(ATO)in the Human Myelodysplastic Syndrome Cell Line SKM-1[J].Indian Journal of Hematology&Blood Transfusion,2016,32(4):412-417.
[17]Adès L,Itzykson R,Fenaux P.Myelodysplastic syndromes[J].Lancet,2014,383(9936):2239-2252.
[18]Traina F,Visconte V,Elson P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia,2014,28(1):78-87.
[19]Wu L,Shi W,Xiao L,et al.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome[J]. Journal of Translational Medicine,2016,14(1):66.
[20]Wang J,Yi Z,Wang S,et al.The effect of decitabine on megakaryocyte maturation and platelet release[J].Thrombosis&Haemostasis,2011,106(2):337-343.